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Introduction. Differentiation syndrome (DS) is a life
threatening  complication  that  may  occur  during  the 
treatment of acute promyelocytic leukemia (APL) by 
all trans-retinoic acid (ATRA) therapy.
occur after 2 to 21 days of treatment and are generally 
an increase in the white blood cell count (WBC), fever, 
weight  gain,  dyspnoea,  pleural  effusion,  and 
pulmonary  infiltrates  on  chest  radiograph.    Some 
patients  may  develop  renal  failure,  hypotension,  and 
pericardial effusion.
2
We are reporting what to our know
case  of  DS  in  a  relapsed  refractory  acute  myeloid 
leukemia (AML) patient receiving decitabine.
Case Report. 44-year-old male patient with a relapsed 
refractory  AML  t(8;21).  He  had  initially  received 
multiple  courses  of  chemotherapy.  Aft
complete  remission  he  underwent  a  donor
allogenic  peripheral stem cell  transplant. The  patient 
presented  to  our  facility  16  months  later  with  his 
second relapse.  A bone marrow aspirate (BMA) and 
biopsy  showed  more  than  50%  myeloblast
Cytogenetics  revealed  Karyotype  46  XY, 
t(8;21)(q22;q22),  t(4;20)(q22;q12),  [19]/46,XY[1]. 
FLT-3 ITD was negative. Flowcytometry showed that 
blasts (CD45 dim) account for approximately 50% of 
the cells, CD13, CD33, CD34 and CD19 were positive. 
CD56  CD117  and  HLADR  were  also  positive. 
Treatment  was  initiated  with  decitabine  (15  mg/m
intravenous  (IV)  daily  for  5  days  repeated  every  4 
weeks) with palliative intent. 
Decitabine  (5-aza-2'-deoxycytidine)  is  a 
hypomethylating  agent  which  has  demonstrated 
activity  in  Myelodysplastic  Syndrome  (MDS) and in 
secondary leukemia.
3 The first two  cycles were well 
tolerated.  On  the  twelfth  day  of  the  third  cycle,  the 
patient  presented  with  fever  39
o C;  chills;  rigors; 
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Differentiation syndrome (DS) is a life-
threatening  complication  that  may  occur  during  the 
treatment of acute promyelocytic leukemia (APL) by 
retinoic acid (ATRA) therapy.
1 Signs usually 
occur after 2 to 21 days of treatment and are generally 
increase in the white blood cell count (WBC), fever, 
weight  gain,  dyspnoea,  pleural  effusion,  and 
pulmonary  infiltrates  on  chest  radiograph.    Some 
patients  may  develop  renal  failure,  hypotension,  and 
ledge is the first 
case  of  DS  in  a  relapsed  refractory  acute  myeloid 
leukemia (AML) patient receiving decitabine.
old male patient with a relapsed 
21).  He  had  initially  received 
multiple  courses  of  chemotherapy.  After  his  second 
complete  remission  he  underwent  a  donor-matched 
allogenic  peripheral stem cell  transplant. The  patient 
presented  to  our  facility  16  months  later  with  his 
second relapse.  A bone marrow aspirate (BMA) and 
biopsy  showed  more  than  50%  myeloblasts 
Cytogenetics  revealed  Karyotype  46  XY, 
t(8;21)(q22;q22),  t(4;20)(q22;q12),  [19]/46,XY[1]. 
3 ITD was negative. Flowcytometry showed that 
blasts (CD45 dim) account for approximately 50% of 
the cells, CD13, CD33, CD34 and CD19 were positive. 
and  HLADR  were  also  positive. 
Treatment  was  initiated  with  decitabine  (15  mg/m
2
intravenous  (IV)  daily  for  5  days  repeated  every  4 
deoxycytidine)  is  a 
hypomethylating  agent  which  has  demonstrated 
ty  in  Myelodysplastic  Syndrome  (MDS) and in 
The first two  cycles were well 
tolerated.  On  the  twelfth  day  of  the  third  cycle,  the 
C;  chills;  rigors; 
cough,  dyspnea;  and  generalized  edema.  The  patient 
looked  ill,  vital  signs  showed  blood  pressure  80/50, 
oxygen saturation 91% on room air. Lung auscultation 
revealed  occasional  fine  basal  crackles.  There  was 
bilateral  lower  limb  pitting  edema  but  no  apparent 
septic foci. Complete blood counts (CBC) showed tot
white cell count (TLC) 5,400/uL; haemoglobin: 10/ dL, 
platelet  count  5,000/  uL  and  neutrophils  3,200/  uL. 
Blood, urine and sputum cultures were all negative and 
a  normal  chest  X-ray  (CXR).  An  empirical  broad
spectrum  antimicrobial  was  started  but  no  gro
factors were prescribed. The patient was transferred to 
the intensive care unit due to marked deterioration in 
his  condition.  Chest  auscultation  revealed  bilateral 
wide spread crackles. A repeat CXR showed bilateral 
areas of infiltrates with consolidat
showed  an  increase  in  TLC  11,800/  uL;  ANC 
5,800/uL;  Hemoglobin:  8.1  g/dL  and  Platelet  count 
20,000/ uL. Repeated pan cultures with each spike of 
fever results were negative. A high resolution CT scan 
of  the  lungs  revealed  bilateral  patches  of  alveolar 
infiltrates  and  areas  of  consolidation  mainly  in  the 
upper  lobes,  air  broncho-gram  was  seen  inside.  No 
cavitations  or  ring  shadows  suggestive  of  fungal 
infections were observed. 
This clinical picture was highly suggestive of DS 
that  is  often  seen  in  patients  with  APL  on  ATRA. 
Bronchoscopy  and  broncho
were  recommended  but  the  patient  refu
clinical  concern that  the  patient  was  suffering  a  DS 
similar  to  the  ATRA  syndrome
milligrams  IV  was  given  and  lead  to    a  dramatic 
improvement of his symptoms.  He was maintained on 
dexamethasone  (DXM)  10  mg  IV  twice  daily  wi
marked  subjective,  clinical  and  radiological 
improvement (Figure 2). The patient was discharged 
shortly  afterwards  when  he  was  asymptomatic  and
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
This  is  an  Open  Access  article  distributed  under  the  terms  of  the  Creative  Commons  Attribution  License
permits unrestricted use, distribution, and reproduction in any medium, 
cough,  dyspnea;  and  generalized  edema.  The  patient 
ked  ill,  vital  signs  showed  blood  pressure  80/50, 
oxygen saturation 91% on room air. Lung auscultation 
revealed  occasional  fine  basal  crackles.  There  was 
bilateral  lower  limb  pitting  edema  but  no  apparent 
septic foci. Complete blood counts (CBC) showed total 
white cell count (TLC) 5,400/uL; haemoglobin: 10/ dL, 
platelet  count  5,000/  uL  and  neutrophils  3,200/  uL. 
Blood, urine and sputum cultures were all negative and 
ray  (CXR).  An  empirical  broad-
spectrum  antimicrobial  was  started  but  no  growth 
factors were prescribed. The patient was transferred to 
the intensive care unit due to marked deterioration in 
his  condition.  Chest  auscultation  revealed  bilateral 
wide spread crackles. A repeat CXR showed bilateral 
areas of infiltrates with consolidation (Figure 1). CBC 
showed  an  increase  in  TLC  11,800/  uL;  ANC 
5,800/uL;  Hemoglobin:  8.1  g/dL  and  Platelet  count 
. Repeated pan cultures with each spike of 
fever results were negative. A high resolution CT scan 
of  the  lungs  revealed  bilateral  patches  of  alveolar 
infiltrates  and  areas  of  consolidation  mainly  in  the 
gram  was  seen  inside.  No 
itations  or  ring  shadows  suggestive  of  fungal 
This clinical picture was highly suggestive of DS 
that  is  often  seen  in  patients  with  APL  on  ATRA. 
Bronchoscopy  and  broncho-alveolar  lavage  (BAL) 
were  recommended  but  the  patient  refused.  Due  to 
that  the  patient  was  suffering  a  DS 
similar  to  the  ATRA  syndrome,  Hydrocortisone  100 
milligrams  IV  was  given  and  lead  to    a  dramatic 
improvement of his symptoms.  He was maintained on 
dexamethasone  (DXM)  10  mg  IV  twice  daily  with 
marked  subjective,  clinical  and  radiological 
. The patient was discharged 
shortly  afterwards  when  he  was  asymptomatic  andMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 1. Chest X-ray showing bilateral lung infiltrates
clinically stable. 
A  pseudo-differentiation  syndrome  (PDS)  was 
suspected in a patient with relapsing refractory AML, 
treated  with  decitabine  with  palliative  intent.  The 
patient’s clinical presentation, radiological findings; in 
addition to the absence of pre-existing lung pathology, 
negative repeated pan cultures as well as good response 
to  DXM  all  favor  DS.  In  the  absence  of  biological 
diagnostic criteria of DS, diagnosis made on clinical 
grounds  by  the  association  of  at  least  three  of  the 
following signs, in the absence of other causes: fever, 
weight  gain,  respiratory  distress,  lung  infiltrates, 
pleural or pericardial effusion, hypotension, and renal 
failure.
1 Our  patient  fulfilled  five  out  of  the  eight 
mentioned  criteria.  Other  conditions  including 
bronchopneumonia in an immunocompromised patient, 
Pneumocystis  Jiroveci  Pneumonia  (PCP)  and  fungal 
lung infection were ruled out. A trial of steroids was 
Figure 2. Chest X-ray showing marked improvement with steroid 
treatment
successful to control fever, dyspnea and constitutional 
symptoms, as well as reversing the CXR findings (see 
figures 1 and 2). 
Conclusions. This case supports the preliminary data 
that  there  might  be  biological  activity  of  low  dose 
decitabine  in  AML  and  suggests that  clinical 
precautions similar to those implemented for theATRA 
syndrome  in  ATRA-treated  APL  patients  should  be 
considered in  Decitabine-treated  AML  with  myeloid 
differentiation. The literature proved that patients with 
APL  whose  blasts  express  CD13  had  higher  risk  to 
develop DS,
1 this may initiate further research whether 
patients  with  AML  with  positive  CD13  may  carry 
higher  risk  to  develop  differentiation  syndrome  with 
hypomethylating agents.
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